Twist Bioscience Corporation
NASDAQ:TWST · NASDAQ Global Select
+$2.15 today
Vol 3.93M · Avg 1.53M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-16.4%
avg -12.2%
ROIC
-24.1%
avg -45.9%
ROA
-12.1%
avg -39.8%
Analysis
ROA is currently the strongest return metric at -12.1% versus its period average of -39.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Emily Marine Leproust | Co-Founder, Board Chair & Chief Executive Officer | $1.78M | — | 53 | $844,607.00 | 1.36% |
Patrick John Finn | President & Chief Operating Officer | $1.27M | — | 54 | $274,804.00 | 0.44% |
Adam Laponis | Chief Financial Officer | $850,687.00 | — | 49 | $112,675.00 | 0.18% |
Paula Green | Senior Vice President of Human Resources | $778,322.00 | — | 58 | $120,705.00 | 0.19% |
Dennis Cho | Chief Legal Officer & Corporate Secretary | $749,014.00 | — | 55 | $119,692.00 | 0.19% |
Michael Fero | Chief Information Officer | — | — | — | — | — |
Robert F. Werner | Vice President & Chief Accounting Officer | — | — | 53 | $46,827.00 | 0.08% |
Siyuan Chen | Chief Technology Officer | — | — | — | — | — |
Nicole Moreno | Senior Vice President of Sales & Support | — | — | — | — | — |
Colby Souders | Chief Scientific Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
141
$29.23M
Net Sentiment
$29.23M
Net selling
Most Active
Leproust Emily M.
29 transactions
1–10 of 141
Analysis
Insiders reported 0 buys worth $0.00 and 141 sells worth $29.23M over the last 12 months. That adds up to net selling of $29.23M. Leproust Emily M. was the most active insider with 29 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A7 analysts |
| Revenue | N/A | N/A | +103.0% | +25.0% (10yr)8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | N/A | N/A8 analysts |
Analysis
Recent growth has been strongest in Revenue at +103.0% over three years. Forward estimates point to Revenue at +25.0% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.89B
uniQure N.V.
NASDAQ:QURE
$2.93B
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.65B
Clover Health Investments, Corp.
NASDAQ:CLOV
$2.54B
Mesoblast Limited
NASDAQ:MESO
$1.85B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.53B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.21B
QuidelOrtho Corporation
NASDAQ:QDEL
$911.73M
BGM Group Ltd.
NASDAQ:BGM
$72.10M
Who manages TWST?
Twist Bioscience Corporation (TWST) lists 10 active executives. The top listed executive is Michael Fero, Chief Information Officer.
Are TWST insiders buying or selling?
Recent insider activity shows net selling of $27.97M.
Explore More
Continue the stock analysis
Jump to another research area for this company.